We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter.
- Authors
LaBarbera, Kelsie M.; Sheline, Yvette I.; Izzo, Nicholas J.; Yuede, Carla M.; Waybright, Lora; Yurko, Raymond; Edwards, Hannah M.; Gardiner, Woodrow D.; Blennow, Kaj; Zetterberg, Henrik; Börjesson-Hanson, Anne; Morgan, Roger; Davis, Charles S.; Guttendorf, Robert J.; Schneider, Lon S.; DeKosky, Steven; LeVine III, Harry; Grundman, Michael; Caggiano, Anthony O.; Cirrito, John R.
- Abstract
The selective increase in CSF A oligomers but not monomers in the two patients with CT1812 treatment is consistent with preclinical evidence that CT1812 selectively displaces oligomeric over monomeric A [[3]]. Eligibility criteria for the study included a diagnosis of mild-moderate AD (Mini-Mental State Examination score 18-26) and either an AD-positive amyloid positron emission tomography scan or a positive CSF result for AD biomarkers (Additional file 1) within 12 months before or at screening. The observed selective increase in CSF A oligomers also suggests that there is a displaceable pool of A oligomers in the AD central nervous system and provides early evidence that the mechanism of action of CT1812 elucidated preclinically translates to the clinic. A phase 1b randomized clinical trial of CT1812 to measure A oligomer displacement in Alzheimer's disease using an indwelling CSF catheter.
- Subjects
ALZHEIMER'S disease; CLINICAL trials; IMPLANTABLE catheters; LEWY body dementia; RETENTION of urine; CEREBROSPINAL fluid shunts
- Publication
Translational Neurodegeneration, 2023, Vol 12, Issue 1, p1
- ISSN
2047-9158
- Publication type
Abstract
- DOI
10.1186/s40035-023-00358-w